Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Liu, Albert Y ^a,b   Vittinghoff, Eric ^b   Sellmeyer, Deborah E ^c   Irvin, Risha ^a   Mulligan, Kathleen ^b   Mayer, Kenneth ^d   Thompson, Melanie ^e   Grant, Robert ^b,f   Pathak, Sonal ^g   O'Hara, Brandon ^g   Gvetadze, Roman ^g   Chillag, Kata ^h   Grohskopf, Lisa ^h   Buchbinder, Susan P ^a,b  

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d FENWAY INSTITUTE   (United States)

^e AIDS Research Consortium of Atlanta   (United States)

^f GLADSTONE INSTITUTES   (United States)

^g NORTHROP GRUMMAN CORPORATION   (United States)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TENOFOVIR DISOPROXIL; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADULT; ARTICLE; BONE DENSITY; COHORT ANALYSIS; CONTROLLED STUDY; DENSITOMETRY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MALE; MALE HOMOSEXUAL; PREVALENCE; PROPHYLAXIS; SIDE EFFECT; ADOLESCENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FRACTURE; HOMOSEXUALITY; METHODOLOGY; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; PREVENTIVE HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS; UNITED STATES;

ABSORPTIOMETRY, PHOTON; ADENINE; ADOLESCENT; ADULT; ANTI-HIV AGENTS; BONE DENSITY; ELIGIBILITY DETERMINATION; FRACTURES, BONE; HIV SERONEGATIVITY; HOMOSEXUALITY, MALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PREVENTIVE HEALTH SERVICES; SAN FRANCISCO; YOUNG ADULT;

EID: 80052279128     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023688     Document Type: Article

References (47)

1. Brown TT, Qaqish RB, (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20: 2165-2174.
2. Calmy A, Fux CA, Norris R, Vallier N, Delhumeau C, et al. (2009) Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis 200: 1746-1754.
3. Jacobson DL, Spiegelman D, Knox TK, Wilson IB, (2008) Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr 49: 298-308.
4. Sharma A, Flom PL, Weedon J, Klein RS, (2010) Prospective study of bone mineral density changes in aging men with or at risk for HIV infection. AIDS 24: 2337-2345.
5. Pollock E, Klotsas AE, Compston J, Gkrania-Klotsas E, (2009) Bone health in HIV infection. Br Med Bull 92: 123-133.
6. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, et al. (2009) Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 51: 554-561.
7. Mallon PW, (2009) HIV and bone mineral density. Curr Opin Infect Dis 23: 1-8.
8. Burns DN, Dieffenbach CW, Vermund SH, (2010) Rethinking prevention of HIV type 1 infection. Clin Infect Dis 51: 725-731.
9. Liu AY, Grant RM, Buchbinder SP, (2006) Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. Jama 296: 863-865.
10. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. N Engl J Med.
11. Smith D, Grant R, Weidle P, Lansky A, Mermin J, et al. (2011) Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men. MMWR 60.
12. FEM-PrEP Project: FHI to Initiate Orderly Closure of FEM-PrEP [press release]. Durham (NC): FHI; 2011 Apr 18 [accessed 2011 Apr 18]. Available from:http://www.fhi.org/en/Research/Projects/FEM-PrEP.htm.
13. Baeten J, Celum C, Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 17-20, 2011. Rome. Abstract MOAX010.
14. Thigpen MC, Kebaabetswe PM, Smith DK, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 17-20, 2011. Rome. Abstract WELBC01.
15. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, et al. (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354: 251-260.
16. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, et al. (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. Jama 292: 191-201.
17. Hawkins T, Veikley W, St Claire RL 3rd, Guyer B, Clark N, et al. (2005) Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr 39: 406-411.
18. Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, et al. (2007) Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. Aids 21: 1899-1907.
19. Vourvahis M, Tappouni HL, Patterson KB, Chen YC, Rezk NL, et al. (2008) The pharmacokinetics and viral activity of tenofovir in the male genital tract. J Acquir Immune Defic Syndr 47: 329-333.
20. Martin A, Bloch M, Amin J, Baker D, Cooper DA, et al. (2009) Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis 49: 1591-1601.
21. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, et al. (2010) Comparison of Changes in Bone Density and Turnover with Abacavir-Lamivudine versus Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from the ASSERT Study. Clin Infect Dis 51: 963-972.
22. Perrot S, Aslangul E, Szwebel T, Caillat-Vigneron N, Le Jeunne C, (2009) Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient. J Clin Rheumatol 15: 72-74.
23. Brim NM, Cu-Uvin S, Hu SL, O'Bell JW, (2007) Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome. AIDS Read 17: 322-328, C323.
24. Parsonage MJ, Wilkins EG, Snowden N, Issa BG, Savage MW, (2005) The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 6: 341-346.
25. Woodward CL, Hall AM, Williams IG, Madge S, Copas A, et al. (2009) Tenofovir-associated renal and bone toxicity. HIV Med 10: 482-487.
26. Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Carlson AE, et al. (2010) Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. Biochem Biophys Res Commun 394: 48-53.
27. Grohskopf L, Gvetadze R, Pathak S, et al. (2010) Preliminary analysis of biomedical data from the phase II clinical safety trial of tenofovir disoproxil fumarate (TDF) for HIV-1 pre-exposure prophylaxis (PrEP) among U.S. men who have sex with men (MSM). XVIII International AIDS Conference. Vienna, Austria.
28. GE Health Care Lunar enCORE™ Reference Data Supplement [manual] Madison (WI) Revision 1 2009 May Document number: 0599897.
29. International Society of Clinical Densitometry Official Positions of the International Society of Clinical Densitometry 2007.
30. Woody GE, Donnell D, Seage GR, Metzger D, Marmor M, et al. (1999) Non-injection substance use correlates with risky sex among men having sex with men: data from HIVNET. Drug Alcohol Depend 53: 197-205.
31. Cummings SR, Block G, McHenry K, Baron RB, (1987) Evaluation of two food frequency methods of measuring dietary calcium intake. Am J Epidemiol 126: 796-802.
32. Cockcroft DW, Gault MH, (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41.
33. Prevention and management of osteoporosis. WHO Study Group Geneva (CH) World Health Organization; 2003 WHO technical report series 921.
34. Warming L, Hassager C, Christiansen C, (2002) Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int 13: 105-112.
35. Guthrie JR, Ebeling PR, Hopper JL, Barrett-Connor E, Dennerstein L, et al. (1998) A prospective study of bone loss in menopausal Australian-born women. Osteoporos Int 8: 282-290.
36. Grijsen ML, Vrouenraets SM, Steingrover R, Lips P, Reiss P, et al. (2010) High prevalence of reduced bone mineral density in primary HIV-1-infected men. AIDS 24: 2233-2238.
37. Kim EY, Kwon do H, Lee BD, Kim YT, Ahn YB, et al. (2009) Frequency of osteoporosis in 46 men with methamphetamine abuse hospitalized in a National Hospital. Forensic Sci Int 188: 75-80.
38. Katsuragawa Y, (1999) Effect of methamphetamine abuse on the bone quality of the calcaneus. Forensic Sci Int 101: 43-48.
39. Chou J, Luo Y, Kuo CC, Powers K, Shen H, et al. (2008) Bone morphogenetic protein-7 reduces toxicity induced by high doses of methamphetamine in rodents. Neuroscience 151: 92-103.
40. Plankey MW, Ostrow DG, Stall R, Cox C, Li X, et al. (2007) The relationship between methamphetamine and popper use and risk of HIV seroconversion in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 45: 85-92.
41. Koblin BA, Husnik MJ, Colfax G, Huang Y, Madison M, et al. (2006) Risk factors for HIV infection among men who have sex with men. AIDS 20: 731-739.
42. Buchbinder SP, Vittinghoff E, Heagerty PJ, Celum CL, Seage GR 3rd, et al. (2005) Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr 39: 82-89.
43. Hansen A, Obel N, Nielsen H, Pedersen C, Gerstoft J, (2010) Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. HIV Med.
44. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, et al. (2011) Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202. J Infect Dis 203: 1791-1801.
45. Cassetti I, Madruga JV, Suleiman JM, Etzel A, Zhong L, et al. (2007) The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 8: 164-172.
46. Carr A, Hoy J, (2010) Low bone mineral density with tenofovir: does statistically significant mean clinically significant? Clin Infect Dis 51: 973-975.
47. Liu A, Vittinghoff E, Gandhi M, Huang Y, Chillag K, et al. (2010) Validating Measures of Tenofovir Drug Exposure in a US Pre-exposure Prophylaxis Trial. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA.